U.S. regulatory status

Tirzepatide (compounded)

Also known as Mounjaro · Zepbound · compounded tirzepatide

RestrictedEnforcement discretion ended; broad compounding no longer permitted

Is Tirzepatide (compounded) legal right now?

Tirzepatide is an FDA-approved drug (Mounjaro, Zepbound), not a 503A bulk substance. After the FDA declared its shortage resolved in late 2024, the temporary enforcement discretion for compounding copies ended on February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities; a federal court upheld the FDA's shortage determination in 2025. Broad compounding is no longer permitted — only narrow patient-specific 503A compounding for a documented clinical need remains — and the FDA has been issuing warning letters. In April 2026 the FDA proposed to permanently exclude tirzepatide from the 503B bulks list.

Restricted: Prescription-only, banned, controlled, or under active FDA enforcement.

Current status held since Mar 19, 2025 · last verified Jul 7, 2026 (ET)

Primary source: Federal Register All 3 sources

Where it sits in the process

Nominated(passed)
Under review(passed)
Rulemaking(stalled here — not advancing)
Compounding-legal(not reached)

Not on a path to the 503A list right now. The process stalled or reversed at this stage — read the status above. Sitting at an earlier step is not a sign it will advance.

Next milestoneComment period closes — FDA proposal to exclude tirzepatide from the 503B bulks list — Jul 30, 2026 (in 22 days)

What changed last

Apr 30, 2026
FDA proposed to permanently exclude tirzepatide from the 503B bulks list, alongside semaglutide and liraglutide. This is a proposal in a comment period, not a final change.
Review scheduledView source
Mar 19, 2025
503B enforcement discretion for compounding tirzepatide ended (503A ended February 18, 2025), following the resolved shortage.
EnforcementView source

Status elsewhere

Tirzepatide (compounded): regulatory status by jurisdiction
Jurisdiction	Status	Note
United States (FDA)	Restricted	Enforcement discretion ended Feb 18, 2025 (503A) / Mar 19, 2025 (503B); FDA proposed permanent 503B exclusion (Apr 2026). Narrow 503A exception remains.
Australia (TGA)	Restricted	GLP-1 compounding prohibited since Oct 1, 2024; remains Schedule 4.
United Kingdom (MHRA)	Restricted	Licensed prescription-only medicine; no legitimate compounding pathway; MHRA enforces against unlicensed product.
Sport / anti-doping (WADA)	Unscheduled	Not prohibited; added to the WADA Monitoring Program effective Jan 1, 2026.

Sources & transparency

Sources for this entry

Federal Register — 503B bulk drug substances clinical-need proposal Federal Register · primaryFDA proposes not to include semaglutide, tirzepatide, and liraglutide on the 503B bulks list.
Pharmacy Times — FDA moves to close the door on compounded GLP-1s analysisApril 2026 proposal; enforcement discretion ended; 503A/503B compounding no longer broadly permitted.
EMJ — GLP-1 receptor agonists on WADA Monitoring Program analysisTirzepatide monitored (effective Jan 1, 2026), not prohibited.

Last verified by a human: Jul 7, 2026 (ET) · how we verify
Who runs this: Peptlas Research Team — independent. About us.
What we sell: Nothing. No products, no affiliates, no sponsored placements.

This page reports publicly available regulatory status for information only. It isnot medical or legal advice and makes no health claim. See ourfull disclaimer.